{"id":22914,"date":"2015-11-19T13:25:11","date_gmt":"2015-11-19T12:25:11","guid":{"rendered":"http:\/\/www.fedaiisf.it\/?p=22914"},"modified":"2015-11-19T18:10:21","modified_gmt":"2015-11-19T17:10:21","slug":"stati-uniti-i-medici-dellama-contro-la-pubblicita-dei-farmaci-etici","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/stati-uniti-i-medici-dellama-contro-la-pubblicita-dei-farmaci-etici\/","title":{"rendered":"United States, Ama doctors against direct advertising of ethical drugs"},"content":{"rendered":"<p><strong>THE<img decoding=\"async\" class=\"alignleft\" src=\"http:\/\/www.drfitmd.com\/wp-content\/uploads\/2013\/12\/AMA-Logo.png\" alt=\"\" \/>The US government prohibits producers from communicating<\/strong> to the general public on prescription drugs. This is the request launched by the American medical association (the AMA, the main acronym of US doctors with more than 200,000 members) to put a stop to the wild growth in marketing costs incurred by manufacturers. A continuous rise in costs, is the Ama&#039;s accusation, which has repercussions on prices to the public and thus excludes a growing portion of Americans from accessing treatment.<\/p>\n<p><strong>St<img loading=\"lazy\" decoding=\"async\" class=\"alignright\" src=\"http:\/\/www.marketing-farmaceutico.com\/wp-content\/uploads\/2012\/09\/pubblicita-farmaci.jpg\" alt=\"\" width=\"289\" height=\"218\" \/>According to some research, the promotional costs incurred by pharmaceutical companies<\/strong> for advertising their prescription-strength products, it is worth approximately $4.5 billion annually. Furthermore, recent estimates speak of an increase of approximately 30% in these costs in the last year alone. Currently, advertising communication on ethical drugs is prohibited in most countries, with the only exceptions (among the more advanced countries) of the USA and New Zealand.<\/p>\n<p>(<a href=\"https:\/\/www.federfarma.it\/Edicola\/FiloDiretto\/Filodiretto\/novembre2015\/19-11-2015-00-30-29.aspx\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #0000ff;\">AS \u2013 11\/19\/2015 \u2013 Federfarma<\/span><\/a>)<\/p>\n<p>Related news: <a href=\"http:\/\/www.ama-assn.org\/ama\/pub\/news\/news\/2015\/2015-11-17-ban-consumer-prescription-drug-advertising.page\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #0000ff;\">AMA Calls for Ban on Direct to Consumer Advertising of Prescription Drugs and Medical Devices<\/span><\/a><\/p>\n<p><span style=\"color: #0000ff;\"><a style=\"color: #0000ff;\" href=\"http:\/\/www.fedaiisf.it\/en\/per-i-cittadini-le-aziende-spendono-troppo-in-marketing-in-usa-uk-e-francia-sempre-piu-difficolta-per-gli-informatori-commerciali\/\" target=\"_blank\">For US citizens, companies spend too much on marketing. In the USA, UK and France more and more difficulties for &quot;commercial&quot; Whistleblowers<\/a><\/span><\/p>\n<p>&nbsp;<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter\" src=\"http:\/\/image.slidesharecdn.com\/grassidiapositive-150111120630-conversion-gate01\/95\/linformazione-sui-farmaci-marco-grassi-50-638.jpg?cb=1420999699\" alt=\"\" width=\"401\" height=\"301\" \/><\/p>","protected":false},"excerpt":{"rendered":"<p>Il Governo Usa vieti ai produttori la possibilit\u00e0 di fare comunicazione al grande pubblico sui farmaci con obbligo di prescrizione. E\u2019 la richiesta lanciata dall\u2019American medical association (l\u2019Ama, la principale sigla dei medici statunitensi con pi\u00f9 di 200mila iscritti) per porre un freno alla crescita selvaggia delle spese sostenute dai produttori per il marketing. Una &hellip;<\/p>","protected":false},"author":4,"featured_media":22920,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[54],"class_list":["post-22914","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-marketing"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/22914","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=22914"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/22914\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/22920"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=22914"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=22914"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=22914"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}